NEW YORK, Sept. 15, 2023 /PRNewswire/ —The wind turbine gearbox market size is expected to grow by USD 4.233 billion from 2022 to 2027, accelerating at a CAGR of 6.39% during the forecast period. The wind turbine gearbox market is driven by the increase in offshore wind energy installations. Offshore wind farms are gaining popularity because they do not need land for installation as they are located on the ocean surface, where the wind energy potential is higher. Offshore wind turbines are generally larger than onshore wind turbines, with capacities in the range of 4 MW-10 MW and requiring high-performance gearboxes for lower maintenance and repair. Get more insights of wind turbine market by downloading the free sample report
The Asia-Pacific (APAC) region is projected to hold a 56% share of the wind turbine gearbox market during the forecast period. This growth is primarily driven by increasing energy demand due to population growth and improved living standards in countries like China and India. These nations are actively expanding their renewable energy capacity, particularly in wind energy, to meet emission targets and reduce pollution. China leads the world with 228 GW of wind energy capacity, while India ranks fourth with 35 GW. This emphasis on wind energy is expected to boost the wind turbine gearbox market in the APAC region.
To find preview of the market overviews, market drivers, opportunities, and potentials request a free sample report
Wind Turbine Gearbox Market 2023-2027: Company Analysis
The wind turbine gearbox market is fragmented due to the presence of many global and regional players. The market comprises category-focused, industry-focused, and diversified companies. The global off-grid wind turbine gearbox market is expected to grow rapidly during the forecast period due to the rising height and capacity of wind towers. Hence, the competition among companies is expected to intensify during the forecast. The report analyzes the market’s competitive landscape and offers information on several market companies including Bonfiglioli Riduttori Spa, Dana Inc., Flender GmbH, Gebr. Eickhoff Maschinenfabrik and Eisengiesserei GmbH, General Electric Co., Hottinger Bruel and Kjaer GmbH, ISHIBASHI Manufacturing Co. Ltd., Lenze SE, ME Production Aps, Moventas Gears Oy, Nanjing High Accurate Drive Equipment Manufacturing Group Co. Ltd., Nord Gear Ltd., Porsche Automobil Holding SE, Robert Bosch GmbH, Shandong Qingneng Power Co. Ltd., Siemens AG, Suzlon Energy Ltd., Voith GmbH and Co. KGaA, ZF Friedrichshafen AG, and ZOLLERN GmbH and Co. KG
To know additional highlights and key points on various market segments and their impact in coming years. Buy the full report now
Related Reports:
Offshore Wind Turbine Market: The Offshore Wind Turbine Market is poised to grow by 54975 MT during 2022-2026, accelerating at a CAGR of 24% during the forecast period.
Wind Turbine Generator Market: The wind turbine generator market growth is expected to accelerate at a CAGR of 4.86% and reach the projected value of USD 9.46 billion by 2026.
Wind Turbine Gearbox Market Scope
Report Coverage
Details
Base year
2022
Historic period
2017-2021
Forecast period
2023-2027
Growth momentum & CAGR
Accelerate at a CAGR of 6.39%
Market growth 2023-2027
USD 4232.96 million
Market structure
Fragmented
YoY growth 2022-2023 (%)
5.53
Regional analysis
APAC, Europe, North America, South America, and Middle East and Africa
Performing market contribution
APAC at 56%
Key countries
US, China, India, Germany, and Spain
Competitive landscape
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled
Bonfiglioli Riduttori Spa, Dana Inc., Flender GmbH, Gebr. Eickhoff Maschinenfabrik and Eisengiesserei GmbH, General Electric Co., Hottinger Bruel and Kjaer GmbH, ISHIBASHI Manufacturing Co. Ltd., Lenze SE, ME Production Aps, Moventas Gears Oy, Nanjing High Accurate Drive Equipment Manufacturing Group Co. Ltd., Nord Gear Ltd., Porsche Automobil Holding SE, Robert Bosch GmbH, Shandong Qingneng Power Co. Ltd., Siemens AG, Suzlon Energy Ltd., Voith GmbH and Co. KGaA, ZF Friedrichshafen AG, and ZOLLERN GmbH and Co. KG
Market dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of Contents:
Executive Summary
Market Landscape
Market Sizing
Historic Market Sizes
Five Forces Analysis
Market Segmentation by Type
Market Segmentation by Application
Customer Landscape
Geographic Landscape
Drivers, Challenges, & Trends
Company Landscape
Company Analysis
Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
SHENZHEN, China, 15. September 2023 /PRNewswire/ — VAPORESSO, ein führender Innovator in der Vaping-Branche, freut sich bekanntgeben zu können, dass das Unternehmen bei den prestigeträchtigen MUSE Design Awards mit acht Auszeichnungen ausgezeichnet wurde, darunter sechs goldene und zwei silberne Auszeichnungen. Diese Anerkennung unterstreicht das Engagement von VAPORESSO für Exzellenz in Design und Innovation.
Zu den prämierten Produkten gehört das neueste Angebot der Marke, die ARMOUR-Serie, die aus ARMOUR MAX und ARMOUR S besteht, die soeben erstmals auf der InterTabac 2023, die vom 14. bis 16. September stattgefunden hat, präsentiert wurden. Der VAPORESSO COSS steht für einen bahnbrechenden Wandel in der Vaping-Branche, da er die Probleme bestehender Produkte angeht und ein intuitives Design bietet, das den Vaping-Gewohnheiten der Konsumenten gerecht wird. Diese Produkte, zusammen mit der COSS-Verpackung, dem ECO NANO, LUXE X PRO, LUXE XR MAX, LUXE Q2 und XROS 3 NANO, wurden für ihr kreatives Design und ihren benutzerorientierten Ansatz ausgezeichnet.
Die MUSE Design Awards sind ein internationaler Designwettbewerb, bei dem außergewöhnliche Designs aus aller Welt ausgezeichnet werden. Seine Mission ist es, herausragende Designinnovatoren zu würdigen, zu feiern und zu fördern, was ihn zu einer zentralen Plattform für die Präsentation aufstrebender Stars in verschiedenen Bereichen macht. Die Auszeichnung von acht VAPORESSO-Produkten auf den MUSE Design Awards ist eine bedeutende Anerkennung des Strebens von VAPORESSO nach herausragendem Design und ultimativer Innovation.
„Der Gewinn dieser Auszeichnungen ist ein Beweis für unser Engagement für INNOVATION, ZUVERLÄSSIGKEIT und STIL – die drei zentralen Markenwerte von VAPORESSO”, sagte Jimmy Hu, Vice President von VAPORESSO. „Wir werden unsere Nutzer auch weiterhin in den Mittelpunkt unseres Handelns stellen und bessere und innovativere Produkte anbieten, die ihren Nutzungsanforderungen und ihrem persönlichen Ausdruck voll und ganz gerecht werden.”
VAPORESSO hat es sich zum Ziel gesetzt, neue Maßstäbe in Design und Innovation zu setzen. Diese Auszeichnungen bei den MUSE Design Awards beweisen den Erfolg der Marke in diesem Bestreben. VAPORESSO hat es sich zum Ziel gesetzt, seinen Nutzern Produkte zu bieten, die nicht nur ihren Bedürfnissen gerecht werden, sondern auch ihre Erwartungen übertreffen, und wird auch weiterhin nach Höchstleistungen streben.
Informationen zu VAPORESSO
VAPORESSO wurde 2015 gegründet und setzt sich für die Schaffung einer rauchfreien Welt und die Verbesserung der Lebensqualität seiner Nutzer ein. Durch kontinuierliche Innovation, strenge Qualitätskontrollen und starkes Engagement stellt VAPORESSO Produkte her, die allen Ansprüchen und Stilen von Vape-Konsumenten gerecht werden.
BUDAPEST, Hungary and BASEL, Switzerland and CAMBRIDGE, Mass., Sept. 15, 2023 /PRNewswire/ — Gedeon Richter Plc. (‘Richter’) together with Sumitomo Pharma America, Inc. (‘SMPA’) and Sumitomo Pharma Switzerland GmbH (‘SMPS’) today announce that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) has adopted a positive opinion recommending the approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. The European Commission (“EC”) will review the CHMP recommendation and a final decision on the Marketing Authorization Application is expected to be available in the coming months. The decision will be applicable to all member states of the European Economic Area.
RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age.
“Broadening the therapeutic reach of our core innovative products demonstrates our tireless pursuit of becoming a leading pharmaceutical company to address women’s health issues,” said Dr Peter Turek, Global Head of Women’s Health at Gedeon Richter. “Once fully approved by the EC, this new therapy could offer a viable treatment option for many women living with endometriosis.”
“Endometriosis can impact general physical, mental, and social well-being. Women often go many years before receiving their endometriosis diagnosis. Some will undergo multiple surgeries in an effort to manage their pain, but many have their symptoms continue or return. This recommendation in the EU serves as an important next step towards making this medicine available for more women living with this condition globally,” said Adele Gulfo, Chief Executive Officer, Biopharma Commercial Unit at Sumitomo Pharma America.
This application is supported by two, 24-week, multi-national clinical studies (SPIRIT 1 and SPIRIT 2) in more than 1,200 women with moderate-to-severe pain associated with endometriosis, as well as the 80-week, open-label extension study to assess longer-term use of RYEQO®. Together, these data represent up to two years of efficacy and safety information with RYEQO®.
About Endometriosis Approximately 10% of women of reproductive age have endometriosis. Many women with endometriosis-associated pain are not able to manage their pain symptoms with current treatment options, underscoring the high unmet need for this disease1.
Endometriosis is a disease in which tissue similar to the uterine lining is found outside the uterine cavity, commonly in the lower abdomen or pelvis, on ovaries, the bladder, and the colon. This endometrial-like tissue outside the uterus results in chronic inflammation and can cause scarring and adhesions.
The symptoms associated with endometriosis include painful periods and chronic pelvic pain, painful ovulation, pain during or after sexual intercourse, heavy bleeding, fatigue, and infertility. Endometriosis can also impact general physical, mental, and social well-being.
About RYEQO® RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) is approved for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. RYEQO® contains relugolix, which reduces the amount of estrogen (and other hormones) produced by ovaries, estradiol (an estrogen) which may reduce the risk of bone loss, and norethisterone acetate (a progestin) which is necessary when women with a uterus (womb) take estrogen.
About Richter Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, China, Latin America, and Australia. Having reached a market capitalization of EUR 3.9 billion (USD 4.1 billion) by the end of 2022, Richter’s consolidated sales were approximately EUR 2.0 billion (USD 2.1 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women’s Healthcare, Central Nervous System, and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women’s Healthcare field worldwide. Richter is also active in biosimilar product development.
About Sumitomo Pharma Group Sumitomo Pharma Group is a global pharmaceutical company based in Japan with key operations in the U.S. (Sumitomo Pharma America, Inc.) and Europe (Sumitomo Pharma Switzerland GmbH) focused on addressing unmet patient needs in psychiatry & neurology, oncology, urology, women’s health, rare disease, and cell & gene therapies. With several marketed products in the U.S., Europe, and Canada, a diverse pipeline of early- to late-stage assets, and in-house advanced technology capabilities, Sumitomo Pharma America and Switzerland aim to accelerate discovery, research, and development to bring novel therapies to patients sooner. Sumitomo Pharma America and Switzerland are companies of Sumitomo Pharma Co., Ltd. For more information, please visit https://www.us.sumitomo-pharma.com and LinkedIn to follow us.
1Becker CM, et al. Fertil Steril. 2017 Jul;108(1):125-136.
The global aortic aneurysm market is poised for robust growth, with projected revenues surging from $3.15 billion in 2022 to $3.41 billion in 2023, marking a compound annual growth rate (CAGR) of 8.28%. The market is expected to continue its upward trajectory, reaching $4.84 billion in 2027, with a CAGR of 9.21%.
Key players in the aortic aneurysm market include AbbVie Inc., Cardiatis SA, Cook Medical Inc., Endologix LLC, W L Gore & Associates Inc., JOTEC GmbH, Lombard Medical Limited, Medtronic Plc., Terumo Corporation, MicroPort Scientific Corporation, C R Bard Inc., Arsenal Medical Inc., Boston Scientific Corporation, Endospan Ltd., and LifeTech Scientific Corporation.
Reasons to Purchase
Gain insights into the global aortic aneurysm market across 50+ geographies.
Understand the market’s response to the COVID-19 pandemic.
Assess the impact of the Russia–Ukraine war on agriculture, energy, and mineral commodity supply.
Measure the influence of high global inflation on market growth.
Create regional and country strategies based on local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and market trends.
Understand customer preferences based on the latest market shares.
Benchmark performance against key competitors.
Access data from the report in an excel dashboard format.
Aortic Aneurysm Market Overview
Aortic aneurysms refer to balloon-like growths in the aorta, the major artery responsible for blood transport from the heart through the chest and torso. These aneurysms can result from various factors including medical conditions, genetic issues, and increased pressure, weakening the aorta’s walls. Aortic aneurysms can take on different shapes and are categorized into thoracic aortic aneurysms (TAA) and abdominal aortic aneurysms (AAA). Treatment methods include open surgical repair (OSR) and endovascular aneurysm repair (EVAR), which are conducted in hospitals, clinics, ambulatory surgery centers, and other medical facilities.
Key Market Trends
Technological advancements are a prominent trend in the aortic aneurysm market. Leading companies are investing in innovative technologies to enhance their market position. In May 2023, Striker Corporation acquired Cerus Endovascular Ltd., a UK-based medical device company, to strengthen its global aneurysm treatment solutions.
Recent Acquisition
In May 2023, Striker Corporation acquired Cerus Endovascular Ltd., a UK-based medical device company, aiming to bolster its aneurysm treatment solutions globally.
Regional Insights
North America emerged as the largest region in the aortic aneurysm market in 2022, with Asia-Pacific expected to exhibit the fastest growth during the forecast period. The report covers regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa.
Prevalence of Alcohol and Tobacco Consumption
The increasing prevalence of alcohol and tobacco consumption is projected to drive the aortic aneurysm market. Alcohol and tobacco products, containing nicotine, are known to have adverse effects on the central nervous system and are linked to aortic aneurysms. The rise in consumption of these products has contributed to the condition.
For instance, the World Health Organization (WHO) reported that alcohol consumption results in approximately 3 million deaths annually, while tobacco consumption leads to 7 million deaths worldwide. In the United States, around 12 of every 100 adults are smokers, totaling 28.3 million adults. This increased consumption of alcohol and tobacco is a key factor driving the aortic aneurysm market.
Key Topics Covered:
1. Executive Summary
2. Aortic Aneurysm Market Characteristics
3. Aortic Aneurysm Market Trends And Strategies
4. Aortic Aneurysm Market – Macro Economic Scenario 4.1. COVID-19 Impact On Aortic Aneurysm Market 4.2. Ukraine-Russia War Impact On Aortic Aneurysm Market 4.3. Impact Of High Inflation On Aortic Aneurysm Market
5. Aortic Aneurysm Market Size And Growth 5.1. Global Aortic Aneurysm Historic Market, 2017-2022, $ Billion 5.1.1. Drivers Of The Market 5.1.2. Restraints On The Market 5.2. Global Aortic Aneurysm Forecast Market, 2022-2027F, 2032F, $ Billion 5.2.1. Drivers Of The Market 5.2.2. Restraints On the Market
6. Aortic Aneurysm Market Segmentation 6.1. Global Aortic Aneurysm Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Thoracic Aortic Aneurysm (TAA)
Abdominal Aortic Aneurysm (AAA)
6.2. Global Aortic Aneurysm Market, Segmentation By Treatment , Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Open Surgical Repair (OSR)
Endovascular Aneurysm Repair (EVAR)
6.3. Global Aortic Aneurysm Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Hospitals And Clinics
Ambulatory Surgery Centers (ASCs)
Other End Users
7. Aortic Aneurysm Market Regional And Country Analysis 7.1. Global Aortic Aneurysm Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion 7.2. Global Aortic Aneurysm Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
About ResearchAndMarkets.com ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CHICAGO, Sept. 15, 2023 /PRNewswire/ — The RNA therapeutics industry is poised for a transformative surge in the near future. Breakthroughs in mRNA vaccine technology, exemplified by the rapid development of COVID-19 vaccines, have catapulted RNA-based therapies into the spotlight. This momentum is expected to continue, with RNA therapeutics emerging as a promising modality for treating a wide range of diseases, including cancer, genetic disorders, and rare diseases. With ongoing research and investments in RNA delivery systems, safety profiles, and target-specific therapies, the industry is on the cusp of providing innovative, personalized treatments that can revolutionize healthcare. As regulatory pathways become more defined and manufacturing processes more efficient, we can anticipate a flourishing RNA therapeutics landscape that holds the potential to reshape the future of medicine, offering new hope to patients worldwide.
RNA Therapeutics Market in terms of revenue was estimated to be worth $13.7 billion in 2023 and is poised to reach $18.0 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is largely driven by factors such as the increasing number of partnerships and collaborations among market players and RNA technology manufacturers, expanding modalities for RNA therapeutics, and the rising number of emergency use authorizations and approvals for COVID-19 booster vaccines. The emergence of small activating RNAs (saRNAs) and circular RNAs (circRNAs) has expanded the scope of RNA therapeutics. saRNAs are 21-nucleotide long double-stranded RNAs (dsRNAs) complementary to the promoter region of a targeted gene. They can upregulate gene expression, potentially correcting deficiencies associated with genetic disorders and re-activating tumor suppressor genes in multiple types of cancers. On the other hand, the discontinuation/recalls of RNA therapeutic products is expected to hinder market growth.
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
Product, Type, Indication, End User, And Region
Geographies Covered
North America, Europe, Asia Pacific, and ROW
Report Highlights
Updated financial information / product portfolio of players
Key Market Opportunities
Higher progress in the development of RNA aptamer-based therapeutics
Key Market Drivers
Increasing partnerships and collaborations among market players and RNA technology manufacturers
The vaccines segment accounted for the largest share of the RNA therapeutics market in 2022.
Based on product, the RNA therapeutics market is segmented into drugs and vaccines. In 2022, vaccines represented majority of the market share and is anticipated to maintain this dominance throughout the forecast period. Two key vaccine products that have showcased majority revenue contribution in this segment, include Spikevax (Moderna, Inc.) and Comirnaty (Pfizer, Inc.) vaccines. Additionally, these COVID-19 vaccines showcased a considerable revenue growth between from 2021 and 2022. On the other hand, the recent recall/discontinuation of Spikevax (Moderna, Inc.) is anticipated to hinder the revenue growth post 2022. Increase in the development of innovative RNA medicine companies in the RNA therapeutics market has rendered it the fastest growing segment during the forecast period.
The RNA interference (RNAi) therapeutics segment is expected to grow at the highest CAGR from 2023 to 2028.
Based on the type, the RNA therapeutics market is segmented into RNA interference (RNAi) therapeutics, mRNA therapeutics, antisense oligonucleotide (ASO) therapeutics, and other therapeutics. Factors associated with RNA interference (RNAi) therapeutics such as precision and versatility have increased the potential of RNAi applications in personalized medicine and other clinical applications. On the other hand, the mRNA therapeutics segment accounted for the highest share in the global market in 2022 and is expected to maintain this trend through 2021-2028. The advantages of mRNA over DNA or proteins/peptides coupled with advent of novel vaccine and molecular entities are the key attributive reason to this dominance.
The infectious diseases segment accounted for the largest share in the RNA therapeutics market in 2022.
Based on the indication, the RNA therapeutics market is segmented into infectious diseases, rare genetic diseases/hereditary diseases, and other indications. The large share of the infectious diseases segment is a result of the rapid developments in RNA vaccine manufacturing capabilities for the treatment of infectious diseases along with the outbreak of COVID-19. Demand for mRNA vaccines grew significantly through 2021-2022, for immunization against SARS-COV-2 infection.
Increase in the use of RNA-based therapeutics for the treatment of rare/genetic disorders contributes to the high share of hospitals & clinics.
The RNA therapeutics market is segmented into hospitals and clinics and research settings. The growing use of RNA therapeutics across hospitals and clinics is driven by factors such as the increasing understanding and advancements of RNA-based therapeutics, the growing number of trends in personalized medicine, the increasing prevalence of chronic diseases, and the rising research investments by governments, private foundations, and industry stakeholders.
Europe dominates the global RNA therapeutics market throughout the forecast period.
The global RNA therapeutics market is segmented into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World. Europe leads the market for RNA vaccines, with highest share of revenue in this segment in 2022. North America has emerged as the fastest growing region from 2023 to 2028. The collective revenue share of Europe, across both RNA vaccines and RNA drugs is highest in 2022, and this is set to continue through the forecast period.
1. Increasing partnerships and collaborations among market players and RNA technology manufacturers
Restraints:
1. Discontinuation or recalls of RNA therapeutic products
Opportunities:
1. Higher progress in the development of RNA aptamer-based therapeutics
Challenge:
1. Rapid degradation by ubiquitous RNases in environment and tissues with strong immunogenicity of exogenous RNA
Key Market Players:
The prominent players in the global RNA therapeutics market include Moderna, Inc. (US), Alnylam Pharmaceuticals, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), Ionis Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), Sanofi (France), Arrowhead Pharmaceuticals, Inc. (US), BioNtech SE (Germany), Orna Therapeutics (US), CRISPR Therapeutics (Switzerland), Silence Therapeutics (UK), Astellas Pharma Inc. (Japan), CureVac SE (Germany), Sirnaomics (US), Arcturus Therapeutics Inc. (US) and Arbutus Biopharma (US).
Precision Medicine: RNA-based therapies can be tailored to target specific genetic mutations or disease pathways, allowing for personalized treatments that are more effective and have fewer side effects.
Speed of Development: The rapid development of RNA-based vaccines during the COVID-19 pandemic demonstrated the agility of this technology, which can potentially accelerate the response to emerging diseases and medical challenges.
Versatility: RNA can be engineered to address a wide range of diseases, including genetic disorders, cancer, infectious diseases, and rare diseases, making it a versatile platform for therapeutic development.
Reduced Off-Target Effects: Compared to traditional small molecule drugs, RNA therapies can have a higher degree of specificity, minimizing off-target effects on healthy cells and tissues.
Lower Manufacturing Costs: Advances in RNA synthesis and production techniques are driving down manufacturing costs, potentially making RNA therapies more accessible and affordable.
Targeting Undruggable Proteins: RNA therapeutics can target proteins that were previously considered “undruggable” with small molecules, expanding the range of potential drug targets.
Potential for Gene Editing: RNA-based therapies, such as CRISPR-Cas9, hold promise for precise gene editing and the treatment of genetic diseases at their root cause.
Immunomodulation: RNA molecules can be designed to stimulate or inhibit immune responses, making them valuable tools in the treatment of autoimmune diseases and for enhancing cancer immunotherapies.
Reduced Development Risk: The ability to rapidly iterate and optimize RNA therapies in preclinical and clinical stages can reduce the risks associated with drug development.
Therapeutic Innovation: RNA therapeutics represent a novel class of drugs that can complement existing treatment modalities, offering innovative solutions to unmet medical needs.
These advantages highlight the transformative potential of RNA therapeutics in advancing healthcare and improving patient outcomes in the near future.
Recent Developments:
In February 2023, Moderna, Inc. received authorization from Health Canada for its COVID-19 booster vaccine, mRNA-1273.214 (SpikevaxBivalent Original/Omicron). This vaccine is designed for immunization against COVID-19 in children and adolescents between 6 to 17 years.
In January 2023, the US FDA granted Breakthrough Therapy Designation for Moderna’s investigational mRNA vaccine candidate—mRNA-1345. This vaccine was developed to prevent RSV-associated lower respiratory tract disease (RSV-LRTD) in adults aged 60 years or older.
In September 2022, Alnylam Pharmaceuticals, Inc. received marketing authorization from the European Commission for its RNAi therapy—AMVUTTRA. This treatment is developed for adult patients with stage 1 or stage 2 polyneuropathy, which is hereditary transthyretin-mediated (hATTR).
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
Media company’s employees to participate in a cleanup day in honor of its 90th anniversary.
WASHINGTON, Sept. 15, 2023 /PRNewswire/ — U.S. News & World Report, the global authority in rankings and consumer advice, today announced a partnership with EARTHDAY.ORG to host a cleanup day in Washington, D.C. and around the country in locations where its remote employees reside as part of The Great Global Cleanup, a worldwide campaign to rid the environment of waste and plastic pollution.
In honor of the 90th anniversary of its founding, U.S. News – which is headquartered in Washington, D.C. – is partnering with four community-based organizations on September 19 to provide meaningful service opportunities for its employees in the Washington metropolitan area. In addition to EARTHDAY.ORG, those organizations include D.C. Central Kitchen, Little Lights and the Friendship Academies at D.C. Public Schools.
“Over its 90-year history, U.S. News has believed that employees that work together work better – and that includes giving back to our local community,” said Marion Phillips, III, U.S. News senior vice president, community development & diversity, equity and inclusion. “We are excited to partner with EARTHDAY.ORG to host a cleanup day in Washington, D.C. and around the country for our employees to make even a small step toward a cleaner America – and ultimately, a cleaner planet.”
As a key moment in the Great Global Cleanup’s annual effort, World Cleanup Day 2023 will be celebrated on September 16. Each September since 2018, it has brought together millions of people for the biggest waste collection day in human history. Individuals wishing to participate in a local cleanup in their area can find one on this interactive map.
“Nearly 80% of all trash that makes its way into the oceans is plastic,” said EARTHDAY.ORG president Kathleen Rogers. “Eventually it degrades into tiny pieces called micro-plastics which in turn get into the food chain – so we are all eating plastics! Which is why Earth Day’s theme for 2024 is Planet vs Plastics – calling on all of us to demand a 60% reduction in plastic production by 2040 – to alleviate our trash problem and for the good of our health.”
A conversation between Phillips and Rogers on the global waste problem and how World Cleanup Day is part of the solution is available here.
About U.S. News & World Report U.S. News & World Report is the global leader in quality rankings that empower consumers, business leaders and policy officials to make better, more informed decisions about important issues affecting their lives and communities. A multifaceted digital media company with Education, Health, Money, Travel, Cars, News, Real Estate, Careers and 360 Reviews platforms, U.S. News provides rankings, independent reporting, data journalism, consumer advice and U.S. News Live events. More than 40 million people visit USNews.com each month for research and guidance. Founded in 1933, U.S. News is headquartered in Washington, D.C.
About EARTHDAY.ORG EARTHDAY.ORG‘s mission is to diversify, educate, and activate the environmental movement worldwide. Growing out of the first Earth Day (1970), EARTHDAY.ORG is the world’s largest recruiter to the environmental movement, working with more than 150,000 partners in nearly 192 countries to build environmental democracy. More than 1 billion people now participate in Earth Day actions each year, making it the largest civic observance in the world. Learn more at earthday.org.
